Supported by

Tricuspid / Pulmonary valve

Find all the latest content on tricuspid or pulmonary valve published on this website.

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

479 results

Innovation for transcatheter tricuspid interventions - LIVE case

24 Nov 2024 – From PCR London Valves 2024

Dive into the world of innovation for transcatheter tricuspid interventions. Discuss the remaining challenges associated with currently available options, capture the central role of imaging guidance, and understand the anatomical selection criteria for transcatheter tricuspid valve replacement. Experience a live case from St. Thomas' Hospital, London,...

Innovation for transcatheter tricuspid interventions

Tricuspid valve intervention - Current devices and future perspectives

24 Nov 2024 – From PCR London Valves 2024

Curious about how to tackle the challenges of tricuspid valve interventions? This video dives into the latest devices and strategies, showing you how to select the right approach for each patient.

Watch experienced practitioners treat real-world cases, from atrial functional regurgitation to large annulus gaps and complex...

Tricuspid valve intervention - Current devices and future perspectives

Innovation never stops: Cardiovalve in action!

24 Nov 2024 – From PCR London Valves 2024

Join us as we explore the latest advancements in transcatheter tricuspid valve replacement technologies. This session develops the anatomical and imaging challenges associated with this rapidly developing clinical field and provides an update on the Cardiovalve tricuspid clinical program, illustrated by a recorded case.

Innovation never stops: Cardiovalve in action!

How should I treat a torrential tricuspid valve regurgitation with large coaptation gap size and severe tethered leaflets?

26 Nov 2024

An 84-year-old female patient with severe tricuspid valve regurgitation (TR) and progressive right-sided heart failure signs is referred for diagnosis and treatment. Transoesophageal echocardiography (TEE) reveals isolated torrential TR (5/5) with a large coaptation gap size and tethered leaflets. How would you treat this patient?

Rico Osteresch

Author

Rico Osteresch
How should I treat a torrential tricuspid valve regurgitation with large coaptation gap size and severe tethered leaflets?

Severe tricuspid regurgitation: repair or replace?

15 Nov 2024

An 87-year-old male patient with severe tricuspid regurgitation, a history of pacemaker implantation, and atrial fibrillation seeks advanced treatment options to improve his declining exercise capacity and daily activities.

#div-gpt-pcro_sidebar_topic {display:none !important;}

Henryk Dreger

Author

Henryk Dreger
Severe tricuspid regurgitation: repair or replace?

Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE study

30 Oct 2024

In this analysis, the 3-year outcomes of the TRILUMINATE study are presented, evaluating the long-term effectiveness of the TriClip T-TEER system on TR reduction, right ventricular remodeling, quality of life, and heart failure symptoms.

Marta Belmonte

Reviewer

Marta Belmonte
Nicola Ryan

Reviewer

Nicola Ryan
Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE study

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali

Alessandro Sticchi

Author

Alessandro Sticchi
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

Large-bore mechanical thrombectomy vs catheter-directed thrombolysis for treatment of intermediate-risk pulmonary embolism: primary outcomes from the PEERLESS randomized controlled trial

30 Oct 2024

Elad Asher provides his take on the PEERLESS trial presented by Wissam A. Jaber at TCT 2024 in Washington.

Elad Asher

Author

Elad Asher
Large-bore mechanical thrombectomy vs catheter-directed thrombolysis for treatment of intermediate-risk pulmonary embolism

PCR @ TCT 2024 - Get the international perspective!

27 Oct 2024

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

PCRonline @ TCT 2024 - get the international perspective!

Tricuspid and other interventions for valvular disease

05 Oct 2024 – From AICT-AsiaPCR 2024

Immerse yourself in this captivating session featuring selected clinical case submissions from the AICT-AsiaPCR 2024 conference. Explore a wide range of interventional challenges, including device closure of ruptured sinus of Valsalva aneurysm, balloon valvotomy during pregnancy in a double orifice mitral valve, and unusual femoral complications....

Tricuspid and other interventions for valvular disease